Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tandem Diabetes Care has commercialized advanced automated insulin delivery systems including the t:slim X2 Insulin Pump and the Tandem Mobi System, both powered by Control-IQ+ technology. These systems are FDA-cleared for use in adults and children with type 1 or type 2 diabetes requiring insulin. Clinical studies have demonstrated improved glycemic control ("time in range") and reduced hypoglycemia with these devices. The company continues to innovate with next-generation patch pumps and digital platforms.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tandem Diabetes Care.